Anzeige
Mehr »
Login
Freitag, 10.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
100 % Anstieg in zwei Tagen: Das technische Signal, das Wall Streets Bären in Panik versetzt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40MKU | ISIN: CA05353D2023 | Ticker-Symbol: 1BU
München
10.01.25
08:05 Uhr
0,440 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
AVANT BRANDS INC Chart 1 Jahr
5-Tage-Chart
AVANT BRANDS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,4260,59011:36
ACCESSWIRE
598 Leser
Artikel bewerten:
(2)

Avant Brands Inc. Announces Voting Results From 2024 Annual General Meeting of Shareholders

Finanznachrichten News

KELOWNA, BC / ACCESSWIRE / May 30, 2024 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or the "Company"), a leading producer of innovative and award-winning cannabis products, held its annual general meeting of shareholders of the Company (the "Shareholders") on May 30, 2024 (the "Meeting").

40,063,347 of the Company's issued and outstanding common shares, representing 14.08% of the total issued and outstanding common shares of the Company, were represented in person or by proxy at the Meeting. Note that Mr. Michael Blady, originally listed as a nominee for reappointment as a Director in the information circular, has informed the Company of his decision not to stand for re-election, as announced on May 9, 2024. Consequently, Mr. Blady was not considered for reappointment.

The complete voting results from the Meeting are as follows:

1. Election of Directors

Each of the six nominees listed in the management information circular of the Company dated April 15, 2024 (the "Circular") were elected to hold office until the next annual meeting of Shareholders or until their successor is duly elected or appointed. Proxies were tabulated as follows:

2. Appointment of Auditor

Ernst & Young LLP was re-appointed as auditor ("Auditor") of the Company for the ensuing year at a remuneration to be fixed by the Company's Board of Directors. Proxies were tabulated as follows:

About Avant Brands Inc.

Avant is an innovative, market-leading premium cannabis company. Avant has multiple operational production facilities across Canada, which produce high-quality, handcrafted cannabis products based on unique and exceptional cultivars.

Avant offers a comprehensive product portfolio catering to recreational, medical, and export markets. Our renowned consumer brands, including BLK MKT, Tenzo, Cognoscente, flowr and Treehugger, are available in key recreational markets across Canada. Avant's products are distributed globally to Australia, Israel and Germany, with its flagship brand BLK MKT currently being sold in Israel. Additionally, Avant's medical cannabis brand, GreenTec, serves qualified patients nationwide through its GreenTec Medical portal and trusted medical cannabis partners.

Avant is a publicly traded corporation listed on the Toronto Stock Exchange (TSX: AVNT) and accessible to international investors through the OTCQX Best Market (OTCQX: AVTBF) and Frankfurt Stock Exchange (FRA: 1BU0). Headquartered in Kelowna, British Columbia, Avant operates in strategic locations, including British Columbia, Alberta, and Ontario.

For more information about Avant, including access to investor presentations and details about its consumer brands, please visit www.avantbrands.ca.

For further inquiries, please contact:
Investor Relations at Avant Brands Inc.
1-800-351-6358
ir@avantbrands.ca

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements relating to Avant Brands Inc.'s future performance, growth prospects, strategic initiatives, and anticipated outcomes. Forward-looking statements are often identified by terms such as 'may', 'will', 'should', 'expect', 'anticipate', 'could', 'intend', 'target', 'project', 'estimate', 'believe', 'predict', 'potential', 'plan', 'objective', 'contemplate', 'seek', 'aim', 'continue', 'budget', 'forecast', 'projections', 'outlook', 'strategy', 'priority', 'goal', 'aim', 'pursue', 'on track', 'initiative', 'expand', 'maintain', 'monitor' and similar expressions or their negatives.

These forward-looking statements are based on certain assumptions, including but not limited to the current regulatory environment, market conditions, and Avant Brands Inc.'s business strategies. However, forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those anticipated in such statements. These risks and uncertainties include, but are not limited to, changes in consumer preferences, regulatory changes, market competition, and the impact of geopolitical events.

Readers are cautioned that the foregoing list of assumptions, risks, and uncertainties is not exhaustive. Forward-looking statements are inherently uncertain and may not prove to be accurate. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements, as there can be no assurance that the plans, intentions, or expectations upon which they are based will occur.

The forward-looking statements contained in this press release are made as of the date of this release, and Avant Brands Inc. undertakes no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

SOURCE: Avant Brands Inc.



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.